Physiology of the parietal cell and therapeutic implications

Pharmacotherapy

Volumn 23, Issue 10 I, 2003, Pages

  Sachs, George ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; G PROTEIN COUPLED RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG BINDING SITE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; STOMACH PH;

ANIMALS; GASTRIC ACID; H(+)-K(+)-EXCHANGING ATPASE; HISTAMINE H2 ANTAGONISTS; HUMANS; MODELS, BIOLOGICAL; PARIETAL CELLS, GASTRIC; PROTEIN BINDING;

EID: 0141865620     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.13.68S.31931     Document Type: Conference Paper

References (21)

1. Modlin IM, Sachs G, eds. Inhibition of the gastric acid pump. In: Acid related diseases: biology and treatment. Konstanz, Germany: Schnetztor-Verlag GmbH D-Konstanz, 1998:126-45.
2. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118:S9-31.
3. Nwokolo CU, Smith JT, Garvey C, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990;4(suppl 1):29-45.
4. Teyssen S, Chari ST, Scheid J, Singer MV. Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects. Dig Dis Sci 1995;40:247-55.
5. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990;99:345-51.
6. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992;51(suppl 1):59-67.
7. +-adenosine triphosphatase α subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 1995;109:1134-41.
8. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17:22-37.
9. Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, Iga T. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet 1998;23:19-26.
10. Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 2002;123:1588-97.
11. Kromer W. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. Scand J Gastroenterol 2001;36(suppl 234):3-9.
12. Kromer W. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds. Digestion 1995;56:443-54.
13. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438-46.
14. Simon B, Muller P, Pascu O. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003;15:791-9.
15. Kromer W, Kruger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 1998;56:57-70.
16. Judmaier G, Koelz HR. Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. Aliment Pharmacol Ther 1994;8:81-6.
17. Fennerty MB. NSAID-related gastrointestinal injury. Evidence-based approach to a preventable complication. Postgrad Med 2001;110:87-94.
18. 2 antagonists and proton pump inhibitors. Ital J Gastroenterol Hepatol 1999;31:S73-8.
19. Pratha V, Karlstadt R, Lynn RB, Lane JR, Hogan DL. Gastric pH may not be an accurate indicator of gastric acidity [abstr]. Am J Gastroenterol 2001;96:S64.
20. Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(suppl 1):3-7.
21. Armbrecht U, Abucar A, Hameeteman W, Schneider A, Stockbrügger RW. Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole-comparison of 24-hour intragastric and oesophageal pH. Aliment Pharmacol Ther 1997;11:959-65.